Completed PHASE1/PHASE2 INTERVENTIONAL NCT00032903

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.

Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial

Sponsor: Rhode Island Hospital

Updated 6 times since 2017 Last updated: Jun 2, 2009 Started: Mar 31, 2002 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00032903, this PHASE1/PHASE2 trial focuses on Malignant Glioma and remains completed. Sponsored by Rhode Island Hospital, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rhode Island Hospital
Sigma-Tau Research, Inc.

Data source: Sigma-Tau Research, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Providence, United States